> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zydus Lifesciences Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/zydus-lifesciences-moat/
- Published: 2026-08-16T17:55:26.000Z
- Updated: 2026-08-22T05:13:09.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Zydus Lifesciences Ltd.

A first-pass moat teardown of Zydus Lifesciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**16 Aug 2026 First-pass · \~3 min

5.47 / 10

NARROWProcess/Data-led

First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Zydus Lifesciences Ltd. scores **5.47** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D3Cost Advantage6.5

M · Mechanism✓ Verified verbatim

“Increase in batch sizes, improvement in the overall equipment efficiency of the packing lines and value stream”

**Zydus Lifesciences Ltd.** · Annual Report · p.35

D5Intangible Assets5.7

M · Mechanism✓ Verified verbatim

“Launched the first biosimilar of an Antibody Drug Conjugate (ADC) Trastuzumab Emtansine under the brand name UjviraTM in India.”

**Zydus Lifesciences Ltd.** · FY2021-22 Annual Report · p.10

D2Switching Costs5.5

M · Mechanism✓ Verified verbatim

“We entered into an agreement with CVS Caremark to add ZituvioTM, ZituvimetTM and ZituvimetTM XR tablets to its formulary.”

**Zydus Lifesciences Ltd.** · Earnings Call · p.4

D1Network Effects5.2

M · Mechanism✓ Verified verbatim

“The Company is one of the prominent players in the Indian Pharmaceutical Market (IPM) with a strong foothold across multiple therapies and a field force of nearly 5800 people.”

**Zydus Lifesciences Ltd.** · FY2021-22 Annual Report · p.31

D4Price Discretion5.2

M · Mechanism✓ Verified verbatim

“the USFDA issued an Establishment Inspection Report (EIR) with a VAI status to our transdermal formulation facility located in the Ahmedabad SEZ against an inspection conducted in the month of July, 2024.”

**Zydus Lifesciences Ltd.** · Earnings Call · p.4

D6Efficient Scale4.8

M · Mechanism✓ Verified verbatim

“So, it's still under litigation. So, I think it's very difficult to give any timelines. But as I said, this potentially has the chance to continue for a longer period of time.”

**Zydus Lifesciences Ltd.** · Earnings Call · p.13

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?6.5

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?5.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).